Tuesday, January 08, 2019

DermWireTV: Bristol-Myers Squibb Acquires Celgene, My UV Tracker, More

Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 Billion. Suneva® Medical partners with Healeon Medical, Inc. and Puregraft, LLC to add two new products to its aesthetics portfolio. Unveiled at the 2018 Consumer Electronics Show, the La Roche-Posay My Skin Track UV from L’Oreal is now available in Apple stores in the US and at apple.com. Pulse Biosciences' Nano-Pulse Stimulation technology achieved outstanding clearance rates on sebaceous hyperplasia lesions on the face, new data show.

Watch Video

Monday, December 17, 2018

DermWireTV: 2018 Therapeutics and Device Highlights

2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.

Watch Video

Thursday, December 06, 2018

DermWire TV: Updates from CSF, PsA Guidelines, Revance Data

Cosmetic Surgery Forum celebrates a decade of success. The meeting, featuring a panel of experts in both medical and cosmetic dermatology, wrapped up on Saturday and is already announcing plans for 2019. When it comes to psoriatic arthritis, prescribers should treat to target, new guidelines from the National Psoriasis Foundation and the American College of Rheumatology conclude. Revance Therapeutics may submit a Biologics License Application for long-acting neuromodulator daxibotulinumtoxinA for Injection, known as RT002, in the first half of next year.

Watch Video

Thursday, November 15, 2018

DermWireTV: Bryhali, Xepi Launches; Epionce's New Facility

Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square foot manufacturing facility in Boise, ID. Younger individuals and females are more likely to use tanning beds and those who do are developing melanoma at an earlier age. Xepi (ozenoxacin) 1% Cream from Cutanea Life Sciences is now available for the treatment of impetigo in adults and in pediatric patients two months of age or older.

Watch Video

Wednesday, November 07, 2018

DermWire TV: Dupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness

FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma’s Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. The Skin Cancer Foundation’s 22nd annual Gala raises $600,000 to support the organization’s educational campaigns, community programs, and research initiatives.November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society has information at SweatHelp.org.

Watch Video

Thursday, October 25, 2018

DermWireTV: Updates from ASDS and ISHRS

The Annual meeting of the American Society for Dermatologic Surgery (ASDS) gathered experts in dermatologic surgery in Phoenix. Joel L. Cohen, MD and Shannon Humphrey, MD, who received the 2018 ASDS Award for Outstanding Service, discussed effective cosmetic consults. Diane Berson, MD addressed both medical and device-based approaches to managing acne. The 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) gathered leaders in hair restoration in Hollywood this month. Sharon Keene, MD spoke about the problem of hair loss in women. Nilofer Farjo, MB, ChB, BAO addressed evolving approaches to hair transplantation in patients with scalp psoriasis.

Watch Video

Tuesday, October 09, 2018

DermWireTV: FDA Approvals, Acne Insights, EPI Gets Cloderm

In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US may share a history of acne, but other data highlight the negative impact of acne on quality of life. EPI Health has acquired the rights to Cloderm Cream, 0.1% and its authorized generic from Promius Pharma, LLC.

Watch Video

Wednesday, September 26, 2018

DermWireTV: Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance

Nestle’s Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dollars, gaining the rights to EB-001A, the investigational botulinum neurotoxin type E formulation. EB-001A, currently in phase 2 trials, is characterized by a rapid onset of action of about 24 hours and a short duration of effect of about two to four weeks. Aclaris Therapeutics has been increasing its education to physicians, releasing a new video series featuring dermatologist Dr. Kavita Mariwala. Aclaris markets Eskata, the only product FDA approved for topical treatment of seborrheic keratosis or SK. Sebacia Microparticles are now FDA-cleared for use in the treatment of mild to moderate inflammatory acne.

Watch Video

Wednesday, September 05, 2018

DermWire TV: Altreno's Approval, Psoriasis Insights

Ortho Dermatologics’ Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for Duobrii Lotion for the topical treatment of plaque psoriasis. Only 10 percent of patients with psoriasis feel their condition is under control with their current treatment plans, results of the PlaquePsoriasis.com survey "Psoriasis in America 2018" show. Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to results from multidisciplinary research from the Perelman School of Medicine at the University of Pennsylvania. JW Pharmaceutical and LEO Pharma have signed a global licensing agreement for JW’s novel atopic dermatitis drug candidate JW1601.

Watch Video

Thursday, August 16, 2018

DermWireTV: Almirall/Allergan, LEO/Bayer Deals

Leo Pharma has agreed to acquire Bayer’s global prescription dermatology unit, and Almirall will acquire Allergan’s US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execute a successful strategy. Those are findings from a survey from eRelevance. The FDA has approved IV Poteligeo injection (Kyowa Kirin) for the treatment of adult patients with either relapsed or refractory mycosis fungoides or Sézary syndrome, after at least one prior systemic therapy.

Watch Video

Wednesday, August 01, 2018

DermWireTV: Medical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018

The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dermatology to network and learn in Las Vegas. The meeting, presented by The Dermatology Education Foundation, offered insights on acne, acne scarring, and new treatments like delafloxacin and ozenoxacin.

Watch Video

Wednesday, July 11, 2018

DermWire TV: BrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved

BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify their behavior in attempts to manage disease symptoms, and more than half say the disease has impacted their work productivity. The FDA has approved Qbrexza cloth (glycopyrronium) from Dermira for the topical treatment of primary axillary hyperhidrosis in patients 9 years of age and older.

Watch Video
Load More